richard_ransohr

Two neuroscientists join Biogen Idec

pharmafile | October 30, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen IDEC, richard ransohoff 

Christopher Henderson and Richard Ransohoff have joined Biogen Idec to lead the company’s neurology research and discovery efforts.

Henderson joins as vice president of the firm’s neurology unit, whilst Ransohoff will serve as senior research fellow for neuroimmunology.

Henderson and Ransohoff (pictured) will work collaboratively within Biogen Idec’s R&D wing to identify and accelerate the development of new product candidates and will report directly to Spyros Artavanis-Tsakonas, who is the senior VP and chief scientific officer at Biogen Idec.

Henderson joins Biogen Idec from Columbia University, where he was the Gurewitsch and Vidda foundation professor of rehabilitation and regenerative medicine, with joint appointments in the departments of pathology and cell biology, neurology and neuroscience.

Ransohoff joins Biogen Idec from the Cleveland Clinic, where he served as director of the Neuroinflammation Research Center in the Department of Neurosciences of the Lerner Research Institute; professor of Molecular Medicine at the Lerner College of Medicine at Case Western Reserve University; and staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research.

Tsakonas says: “Transformative medicines result from transformative science. We are bringing together some of the brightest minds in research to create new ways of looking at devastating neurological diseases where there are few, if any, effective therapies. Chris and Richard will help accelerate our efforts to bring innovative new medicines to patients who desperately need them.”

Related Content

Biogen to build billion-dollar plant in Switzerland

Biogen plans to open a $1 billion manufacturing facility in Switzerland, to help Europe deal …

Biogen image

Big pharma partners with government over $100m dementia fund

Lilly, Pfizer, GSK, J&J and Biogen Idec are set to join a $100m Dementia Discovery …

Biogen image

Pharma is boosting pipelines to avoid patent cliff

Pharmaceutical companies have improved their pipelines of new drugs over the last 18 months according …

Latest content